Adage Capital Partners Gp, L.L.C. Cogent Biosciences, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $59.7 Billion
- Q3 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 562,000 shares of COGT stock, worth $18.8 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
562,000Holding current value
$18.8 Million% of portfolio
0.01%Shares
11 transactions
Others Institutions Holding COGT
# of Institutions
219Shares Held
133MCall Options Held
999KPut Options Held
429K-
Vanguard Group Inc Valley Forge, PA11.5MShares$386 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY9.05MShares$304 Million2.42% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA9MShares$302 Million28.14% of portfolio
-
Kynam Capital Management, LP Princeton, NJ7.89MShares$265 Million9.57% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$244 Million0.0% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $2.21B
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...